89 related articles for article (PubMed ID: 10667214)
1. In vitro evaluation of a novel 2,6,9-trisubstituted purine acting as a cyclin-dependent kinase inhibitor.
Giocanti N; Sadri R; Legraverend M; Ludwig O; Bisagni E; Leclerc S; Meijer L; Favaudon V
Ann N Y Acad Sci; 1999; 886():180-2. PubMed ID: 10667214
[No Abstract] [Full Text] [Related]
2. The design and synthesis of purine inhibitors of CDK2. III.
Shum PW; Peet NP; Weintraub PM; Le TB; Zhao Z; Barbone F; Cashman B; Tsay J; Dwyer S; Loos PC; Powers EA; Kropp K; Wright PS; Bitonti A; Dumont J; Borcherding DR
Nucleosides Nucleotides Nucleic Acids; 2001; 20(4-7):1067-78. PubMed ID: 11562960
[TBL] [Abstract][Full Text] [Related]
3. 8-Azapurines as new inhibitors of cyclin-dependent kinases.
Havlicek L; Fuksova K; Krystof V; Orsag M; Vojtesek B; Strnad M
Bioorg Med Chem; 2005 Sep; 13(18):5399-407. PubMed ID: 15993080
[TBL] [Abstract][Full Text] [Related]
4. Synthesis and biological evaluation of selective and potent cyclin-dependent kinase inhibitors.
N'gompaza-Diarra J; Bettayeb K; Gresh N; Meijer L; Oumata N
Eur J Med Chem; 2012 Oct; 56():210-6. PubMed ID: 22982525
[TBL] [Abstract][Full Text] [Related]
5. Synthesis and in vitro biological evaluation of 2,6,9-trisubstituted purines targeting multiple cyclin-dependent kinases.
Zatloukal M; Jorda R; Gucký T; Řezníčková E; Voller J; Pospíšil T; Malínková V; Adamcová H; Kryštof V; Strnad M
Eur J Med Chem; 2013 Mar; 61():61-72. PubMed ID: 22770608
[TBL] [Abstract][Full Text] [Related]
6. Synthesis and biological properties of C-2, C-8, N-9 substituted 6-(3-chloroanilino)purine derivatives as cyclin-dependent kinase inhibitors. Part II.
Oh CH; Kim HK; Lee SC; Oh C; Yang BS; Rhee HJ; Cho JH
Arch Pharm (Weinheim); 2001 Nov; 334(11):345-50. PubMed ID: 11822171
[TBL] [Abstract][Full Text] [Related]
7. Heterobiaryl purine derivatives as potent antiproliferative agents: inhibitors of cyclin dependent kinases. Part II.
Trova MP; Barnes KD; Alicea L; Benanti T; Bielaska M; Bilotta J; Bliss B; Duong TN; Haydar S; Herr RJ; Hui Y; Johnson M; Lehman JM; Peace D; Rainka M; Snider P; Salamone S; Tregay S; Zheng X; Friedrich TD
Bioorg Med Chem Lett; 2009 Dec; 19(23):6613-7. PubMed ID: 19854650
[TBL] [Abstract][Full Text] [Related]
8. Synthesis and biological activity of olomoucine II.
Krystof V; Lenobel R; Havlícek L; Kuzma M; Strnad M
Bioorg Med Chem Lett; 2002 Nov; 12(22):3283-6. PubMed ID: 12392733
[TBL] [Abstract][Full Text] [Related]
9. Indenopyrazoles as novel cyclin dependent kinase (CDK) inhibitors.
Nugiel DA; Etzkorn AM; Vidwans A; Benfield PA; Boisclair M; Burton CR; Cox S; Czerniak PM; Doleniak D; Seitz SP
J Med Chem; 2001 Apr; 44(9):1334-6. PubMed ID: 11311054
[No Abstract] [Full Text] [Related]
10. Synthesis and application of functionally diverse 2,6,9-trisubstituted purine libraries as CDK inhibitors.
Chang YT; Gray NS; Rosania GR; Sutherlin DP; Kwon S; Norman TC; Sarohia R; Leost M; Meijer L; Schultz PG
Chem Biol; 1999 Jun; 6(6):361-75. PubMed ID: 10375538
[TBL] [Abstract][Full Text] [Related]
11. A novel series of highly potent 2,6,9-trisubstituted purine cyclin-dependent kinase inhibitors.
Gucký T; Jorda R; Zatloukal M; Bazgier V; Berka K; Řezníčková E; Béres T; Strnad M; Kryštof V
J Med Chem; 2013 Aug; 56(15):6234-47. PubMed ID: 23829517
[TBL] [Abstract][Full Text] [Related]
12. Biaryl purine derivatives as potent antiproliferative agents: inhibitors of cyclin dependent kinases. Part I.
Trova MP; Barnes KD; Barford C; Benanti T; Bielaska M; Burry L; Lehman JM; Murphy C; O'Grady H; Peace D; Salamone S; Smith J; Snider P; Toporowski J; Tregay S; Wilson A; Wyle M; Zheng X; Friedrich TD
Bioorg Med Chem Lett; 2009 Dec; 19(23):6608-12. PubMed ID: 19846305
[TBL] [Abstract][Full Text] [Related]
13. Recent advances in cyclin-dependent kinase inhibition. Purine-based derivatives as anti-cancer agents. Roles and perspectives for the future.
Haesslein JL; Jullian N
Curr Top Med Chem; 2002 Sep; 2(9):1037-50. PubMed ID: 12171570
[TBL] [Abstract][Full Text] [Related]
14. Zinc(II) complexes with potent cyclin-dependent kinase inhibitors derived from 6-benzylaminopurine: synthesis, characterization, X-ray structures and biological activity.
Trávnícek Z; Krystof V; Sipl M
J Inorg Biochem; 2006 Feb; 100(2):214-25. PubMed ID: 16386795
[TBL] [Abstract][Full Text] [Related]
15. The lethal effects of pharmacological cyclin-dependent kinase inhibitors in human leukemia cells proceed through a phosphatidylinositol 3-kinase/Akt-dependent process.
Yu C; Rahmani M; Dai Y; Conrad D; Krystal G; Dent P; Grant S
Cancer Res; 2003 Apr; 63(8):1822-33. PubMed ID: 12702569
[TBL] [Abstract][Full Text] [Related]
16. In vitro and in vivo pharmacokinetic-pharmacodynamic relationships for the trisubstituted aminopurine cyclin-dependent kinase inhibitors olomoucine, bohemine and CYC202.
Raynaud FI; Whittaker SR; Fischer PM; McClue S; Walton MI; Barrie SE; Garrett MD; Rogers P; Clarke SJ; Kelland LR; Valenti M; Brunton L; Eccles S; Lane DP; Workman P
Clin Cancer Res; 2005 Jul; 11(13):4875-87. PubMed ID: 16000586
[TBL] [Abstract][Full Text] [Related]
17. The p16 status of tumor cell lines identifies small molecule inhibitors specific for cyclin-dependent kinase 4.
Kubo A; Nakagawa K; Varma RK; Conrad NK; Cheng JQ; Lee WC; Testa JR; Johnson BE; Kaye FJ; Kelley MJ
Clin Cancer Res; 1999 Dec; 5(12):4279-86. PubMed ID: 10632371
[TBL] [Abstract][Full Text] [Related]
18. Roscovitine inhibits the proliferative activity of immortal and neoplastic human breast epithelial cells.
Mgbonyebi OP; Russo J; Russo IH
Anticancer Res; 1998; 18(2A):751-5. PubMed ID: 9615715
[TBL] [Abstract][Full Text] [Related]
19. Structure-based design of a potent purine-based cyclin-dependent kinase inhibitor.
Davies TG; Bentley J; Arris CE; Boyle FT; Curtin NJ; Endicott JA; Gibson AE; Golding BT; Griffin RJ; Hardcastle IR; Jewsbury P; Johnson LN; Mesguiche V; Newell DR; Noble ME; Tucker JA; Wang L; Whitfield HJ
Nat Struct Biol; 2002 Oct; 9(10):745-9. PubMed ID: 12244298
[TBL] [Abstract][Full Text] [Related]
20. Roscovitine inhibits ongoing DNA synthesis in human cervical cancer.
Vitali L; Yakisich JS; Vita MF; Fernandez A; Settembrini L; Siden A; Cruz M; Carminatti H; Casas O; Idoyaga Vargas V
Cancer Lett; 2002 Jun; 180(1):7-12. PubMed ID: 11911964
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]